Targets › FSHR
10 programs from 8 companies in 14 trials: 5 Phase 4, 4 Phase 2, 3 Phase 3, 2 Phase 1; Genitourinary, Other, Oncology; next expected readout Dec 2026.
G protein-coupled receptor for follitropin, the follicle-stimulating hormone. Mediates FSH signaling through cAMP/protein kinase A (PKA) and phosphatidylinositol-3 kinase (PI3K)/protein kinase B (AKT) pathways to regulate ovarian follicular development and steroidogenesis. (UniProt, P23945)
Open in Phaseline: the race on FSHR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Fundación Santiago Dexeus Font | Follitropin-delta (Rekovelle) 15 mcg/day Recombinant follicle-stimulating hormone (rFSH) | FSHR | Phase 4 | Fertility | Dec 2026 |
| Fundación Santiago Dexeus Font | rhFSH+rhLH (Pergoveris®) Recombinant human follicle-stimulating hormone and recombinant human luteinizing hormone | FSHR, LHR | Phase 4 | Infertility | Aug 2027 |
| University Hospital, Ghent | Corifollitropin Alfa Follicle stimulating hormone receptor agonist | FSHR | Phase 4 | Ovarian Stimulation | Dec 2027 |
| LG Chem | Fang Le Shu (Follitrope) Recombinant follicle-stimulating hormone (rFSH) | FSHR | Phase 4 | Female Infertility | – |
| Merck KGaA | Follitropin (MBJ-0011) Follicle stimulating hormone receptor agonist | FSHR | Phase 3 | Infertility | Sep 2027 |
| Granata Bio | hMG (human menopausal gonadotropin) Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) receptor agonist | FSHR, LHR | Phase 3 | Infertility (IVF Patients) | Nov 2028 |
| Clinique Ovo | Follitropin Delta Follicle stimulating hormone receptor agonist | FSHR | Phase 2 | IVF; Low Ovarian Reserve; Infertility | Aug 2027 |
| Clinique Ovo | HP-hMG (MENOPUR) Highly purified human menopausal gonadotrophin containing FSH and LH | FSHR, LHCGR | Phase 2 | IVF | Aug 2027 |
| Institut Cancerologie de l'Ouest | FSH (Follicle-stimulating hormone) Recombinant gonadotropin that stimulates ovarian follicle development and oocyte maturatio | FSHR | Phase 2 | Breast Cancer | Jan 2028 |
| Qilu Pharmaceutical | Follitropin Alfa Follicle stimulating hormone receptor agonist | FSHR | Phase 1 | Infertility, Female | – |
Infertility (5) IVF (2) Fertility (1) Low Ovarian Reserve (1) Ovarian Stimulation (1) Breast Cancer (1) Infertility, Female (1) Female Infertility (1) Infertility (IVF Patients) (1)
small molecule (9), protein or peptide (1)
Fundación Santiago Dexeus Font (2) Clinique Ovo (2) University Hospital, Ghent (1) Institut Cancerologie de l'Ouest (1) Qilu Pharmaceutical (1) LG Chem (1) Granata Bio (1) Merck KGaA (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.